PDCD1 and neoplasm: In this setting, RT may act as an in situ vaccine by inducing immunogenic cell death, enhancing antigen presentation, and increasing trafficking and activation of tumor-specific T cells, whereas checkpoint blockade prevents PD-1/PD-L1-mediated adaptive resistance and sustains systemic antitumor immunity [85,86,87,88].